{"abstract": "Pfizer\u2019s planned acquisition of Wyeth is a validation of Wyeth\u2019s decision to reduce its reliance on small-molecule drugs.", "web_url": "https://www.nytimes.com/2009/01/27/business/27wyeth.html", "snippet": "Pfizer\u2019s planned acquisition of Wyeth is a validation of Wyeth\u2019s decision to reduce its reliance on small-molecule drugs.", "lead_paragraph": "Molecules.", "print_section": "B", "print_page": "4", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2009/01/27/business/27pfizer.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2009/01/27/business/27pfizer.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}], "headline": {"main": "In Wyeth, Pfizer Sees a Drug Pipeline", "kicker": null, "content_kicker": null, "print_headline": "In Pursuit of a Pipeline of Biological Treatments", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Biotechnology", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Wyeth", "rank": 5, "major": "N"}], "pub_date": "2009-01-26T19:21:15+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Natasha Singer", "person": [{"firstname": "Natasha", "middlename": null, "lastname": "Singer", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/62c902a8-ddbe-56fe-9f2e-11f63f134818", "word_count": 1104, "uri": "nyt://article/62c902a8-ddbe-56fe-9f2e-11f63f134818"}